Search - tctmd.com

Displaying 1 - 20 of 47

Sort: Relevancy | Date

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

Todd Neale

December 22, 2023

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

Shelley Wood

December 19, 2023

News Daily News

Family History of CVD? Low PUFA Intake May Add to Risk

Michael O'Riordan

December 12, 2023

News Daily News

Statin Use Has Plateaued in US Primary Prevention Patients

Michael O'Riordan

December 05, 2023

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

News Conference News AHA 2023

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Todd Neale

November 17, 2023

Presentation AHA 2023

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Presenter: Jamie Kitt

November 17, 2023

News Conference News AHA 2023

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

L.A. McKeown

November 17, 2023

Presentation AHA 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presenter: Jeff Healey

November 16, 2023

News Conference News AHA 2023

Sudden Cardiac Death Declining Among NCAA Athletes

Michael O'Riordan

November 15, 2023

Presentation AHA 2023

Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients

Presenter: William T. Abraham

November 15, 2023

News Conference News AHA 2023

AI Improves Detection of Cardiomyopathy in Pregnancy

L.A. McKeown

November 15, 2023

News Conference News AHA 2023

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Yael L. Maxwell

November 14, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Presentation AHA 2023

Screening For Peripartum Cardiomyopathies Using An AI-Enhanced Digital Stethoscope: A Randomized Clinical Trial

Presenter: Demilade Adedinsewo

November 13, 2023

News Conference News AHA 2023

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

L.A. McKeown

November 13, 2023

News Conference News AHA 2023

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Shelley Wood

November 13, 2023

News Conference News AHA 2023

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

Caitlin E. Cox

November 12, 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP-Lowering KARDIA-1

News Conference News AHA 2023

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Caitlin E. Cox

November 11, 2023

Presentation AHA 2023

Safety and Pharmacodynamic Effects of VERVE-101

Presenter: Andrew Bellinger

November 11, 2023

Advertisement

AHA Selects 2023’s Leading Cardiovascular Research

Who Benefits Most From Semaglutide and How Long Will That Take?

Family History of CVD? Low PUFA Intake May Add to Risk

Statin Use Has Plateaued in US Primary Prevention Patients

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

Reductions in Plaque, Inflammation Appear to Explain Statin Benefit in HIV

Physician Optimised Postpartum Hypertension Treatment (POP-HT) Randomised Trial

Novel AI-Guided CV Risk Prediction Takes Aim at Coronary Inflammation

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Sudden Cardiac Death Declining Among NCAA Athletes

Validation of a Speech Analysis Application to Detect Worsening Heart Failure Events in Ambulatory Heart Failure Patients

AI Improves Detection of Cardiomyopathy in Pregnancy

New CVD Risk Tool Can Spur Even Earlier Talk About Prevention

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Screening For Peripartum Cardiomyopathies Using An AI-Enhanced Digital Stethoscope: A Randomized Clinical Trial

POP-HT: Physician-Guided Self-Monitoring Improves BP After Hypertensive Pregnancy

New PCSK9 Inhibitor Halves LDL: Will Protracted Dosing Make a Difference?

Gene Editing Shuts Off PCSK9 to Lower LDL in HeFH

RNA-Interference Agent Zilebesiran Looks Promising for BP: KARDIA-1

Safety and Pharmacodynamic Effects of VERVE-101

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content